Development of an image analysis screen for estrogen receptor alpha (ERα) ligands through measurement of nuclear translocation dynamics.
We have developed a robust high-content assay to screen for novel estrogen receptor alpha (ERα) agonists and antagonists by quantitation of cytoplasmic to nuclear translocation of an estrogen receptor chimera in 384-well plates. The screen utilizes a green fluorescent protein tagged-glucocorticoid/estrogen receptor (GFP-GRER) chimera which consisted of the N-terminus of the glucocorticoid receptor fused to the human ER ligand binding domain. The GFP-GRER exhibited cytoplasmic localization in the absence of ERα ligands, and translocated to the nucleus in response to stimulation with ERα agonists or antagonists. The BD Pathway 435 imaging system was used for image acquisition, analysis of translocation dynamics, and cytotoxicity measurements. The assay was validated with known ERα agonists and antagonists, and the Library of Pharmacologically Active Compounds (LOPAC 1280). Additionally, screening of crude natural product extracts demonstrated the robustness of the assay, and the ability to quantitate the effects of toxicity on nuclear translocation dynamics. The GFP-GRER nuclear translocation assay was very robust, with z' values >0.7, CVs <5%, and has been validated with known ER ligands, and inclusion of cytotoxicity filters will facilitate screening of natural product extracts. This assay has been developed for future primary screening of synthetic, pure natural products, and natural product extracts libraries available at the National Cancer Institute at Frederick.
Dull
Angie
A
Molecular Targets Laboratory, SAIC-Frederick, Inc., National Cancer Institute-Frederick, Frederick, Maryland 21702, United States. dulla@mail.nih.gov
Goncharova
Ekaterina
E
Hager
Gordon
G
McMahon
James B
JB
D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D047628:Estrogen Receptor alpha / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005189:False Positive Reactions; D005260:Female; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008325:Mammary Neoplasms, Experimental; D051379:Mice; D050506:Mutant Chimeric Proteins / Q000378:metabolism; D021381:Protein Transport; D011960:Receptors, Estrogen / Q000378:metabolism; D011965:Receptors, Glucocorticoid / Q000378:metabolism
D000970:Antineoplastic Agents; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D008024:Ligands; D050506:Mutant Chimeric Proteins; D011960:Receptors, Estrogen; D011965:Receptors, Glucocorticoid; D049452:Green Fluorescent Proteins
Carcinogenesis. 1996 Mar;17(3):585-94
8631149
Proc Natl Acad Sci U S A. 1986 Apr;83(8):2496-500
3458212
J Steroid Biochem Mol Biol. 2005 Dec;97(4):307-21
16162406
J Clin Endocrinol Metab. 1973 Feb;36(2):207-14
4688315
Carcinogenesis. 2001 Mar;22(3):489-97
11238191
Carcinogenesis. 1999 Jul;20(7):1153-60
10383884
JAMA. 2003 Jun 25;289(24):3243-53
12824205
Chem Res Toxicol. 2001 Aug;14(8):1041-50
11511178
Carcinogenesis. 1997 Nov;18(11):2247-53
9395228
Assay Drug Dev Technol. 2003 Dec;1(6):789-800
15090225
Assay Drug Dev Technol. 2005 Aug;3(4):393-400
16180994
Cancer Res. 1988 May 15;48(10):2837-57
3129189
Endocr Relat Cancer. 2004 Dec;11(4):643-58
15613444
BMJ. 2005 Apr 23;330(7497):932
15746106
J Biomol Screen. 1999;4(2):67-73
10838414
Lancet. 2003 Aug 9;362(9382):419-27
12927427
JAMA. 2002 Jul 17;288(3):321-33
12117397
Crit Rev Oncog. 1993;4(4):403-17
8353140
Drugs. 2008;68(14):2059-83
18778124
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):352-6
18334013
Intern Med. 2002 May;41(5):345-50
12058881